Alkermes plc (ALKS)

Alkermes plc is trading at $44.18, up 1.61% on the session. The 50 day average sits at $45.08 and the 200 day at $39.72, which puts the stock in a uptrend. RSI is at 44.7, which reads as weak, and MACD is bullish crossover. Volume is above average.

The nearest support is around $39.84 with resistance near $43.22, so that band frames the current range. Average daily movement is roughly $1.44, or about 3.3% of the share price, which is what any stop placement has to allow for. The overall health score of 53 out of 100 combines a trend score of 50, momentum of 47 and a risk score of 65.

Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.